Skip to content

Study · Not a test of the peptide alone · 2017

10 results

Effect of ulinastatin combined with thymosin alpha1 on sepsis: A systematic review and meta-analysis of Chinese and Indian patients.

Liu D, Yu Z, Yin J, Chen Y, Zhang H, Xin F, Fu H, Wan B

Journal of critical care27 Dec 2016Cited by 27 (Europe PMC)

PMID28069319 (opens in a new tab)DOI10.1016/j.jcrc.2016.12.013 (opens in a new tab)PepBankPUB-28069319
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneSystematic reviewEfficacy outcome

    In septic patients, ulinastatin combined with thymosin α1 decreased 28-day mortality by 36% in a meta-analysis of RCTs.

    In plain wordsIn people with sepsis, ulinastatin plus thymosin α1 lowered 28-day deaths by 36% in pooled trials; the effect of thymosin α1 alone is unknown.

    Peptide
    Thymosin alpha-1
    Outcome
    Decrease28-day mortality
    Study

    n: not reported in source

    Outcome group
    Mortality · Infection

    Measurements

    Mortality decrease
    36%
    28 days

    Source sentences

    Summary
    Treatment of UTI combined with Tα1 (UTI+Tα1) decreased the short-term mortality rate in septic patients by 36%, 35%, and 31% for 28, 60, 90 days, respectively.
    1 context sentence
    Summary · context
    The meta-analysis included 8 randomized controlled trials (N=1112 patients) on UTI-based therapy for sepsis published before July 10, 2016.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneSystematic reviewEfficacy outcome

    In septic patients, ulinastatin combined with thymosin α1 decreased 60-day mortality by 35% in a meta-analysis of RCTs.

    In plain wordsIn people with sepsis, ulinastatin plus thymosin α1 lowered 60-day deaths by 35% in pooled trials; the effect of thymosin α1 alone is unknown.

    Peptide
    Thymosin alpha-1
    Outcome
    Decrease60-day mortality
    Study

    n: not reported in source

    Outcome group
    Mortality · Infection

    Measurements

    Mortality decrease
    35%
    60 days

    Source sentences

    Summary
    Treatment of UTI combined with Tα1 (UTI+Tα1) decreased the short-term mortality rate in septic patients by 36%, 35%, and 31% for 28, 60, 90 days, respectively.
    1 context sentence
    Summary · context
    The meta-analysis included 8 randomized controlled trials (N=1112 patients) on UTI-based therapy for sepsis published before July 10, 2016.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneSystematic reviewEfficacy outcome

    In septic patients, ulinastatin combined with thymosin α1 decreased 90-day mortality by 31% in a meta-analysis of RCTs.

    In plain wordsIn people with sepsis, ulinastatin plus thymosin α1 lowered 90-day deaths by 31% in pooled trials; the effect of thymosin α1 alone is unknown.

    Peptide
    Thymosin alpha-1
    Outcome
    Decrease90-day mortality
    Study

    n: not reported in source

    Outcome group
    Mortality · Infection

    Measurements

    Mortality decrease
    31%
    90 days

    Source sentences

    Summary
    Treatment of UTI combined with Tα1 (UTI+Tα1) decreased the short-term mortality rate in septic patients by 36%, 35%, and 31% for 28, 60, 90 days, respectively.
    1 context sentence
    Summary · context
    The meta-analysis included 8 randomized controlled trials (N=1112 patients) on UTI-based therapy for sepsis published before July 10, 2016.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04HumanNot a test of Thymosin alpha-1 aloneSystematic reviewEfficacy outcome

    In septic patients, ulinastatin combined with thymosin α1 decreased the duration of mechanical ventilation in a meta-analysis.

    In plain wordsIn people with sepsis, ulinastatin plus thymosin α1 shortened time on a ventilator in pooled trials; the effect of thymosin α1 alone is unknown.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseDuration of mechanical ventilation
    Study

    n: not reported in source

    Outcome group
    Intensive care and hospital outcomes · Respiratory

    Source sentences

    Summary
    UTI+Tα1 decreased the duration of mechanical ventilation, APACHE II score, and levels of IL-6 and tumor necrosis factor α.
    1 context sentence
    Summary · context
    The meta-analysis included 8 randomized controlled trials (N=1112 patients) on UTI-based therapy for sepsis published before July 10, 2016.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05HumanNot a test of Thymosin alpha-1 aloneSystematic reviewEfficacy outcome

    In septic patients, ulinastatin combined with thymosin α1 decreased the APACHE II score in a meta-analysis.

    In plain wordsIn people with sepsis, ulinastatin plus thymosin α1 lowered illness severity scores in pooled trials; the effect of thymosin α1 alone is unknown.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseAPACHE II score
    Study

    n: not reported in source

    Outcome group
    Intensive care and hospital outcomes · Whole body

    Source sentences

    Summary
    UTI+Tα1 decreased the duration of mechanical ventilation, APACHE II score, and levels of IL-6 and tumor necrosis factor α.
    1 context sentence
    Summary · context
    The meta-analysis included 8 randomized controlled trials (N=1112 patients) on UTI-based therapy for sepsis published before July 10, 2016.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06HumanNot a test of Thymosin alpha-1 aloneSystematic reviewEfficacy outcome

    In septic patients, ulinastatin combined with thymosin α1 decreased IL-6 levels in a meta-analysis.

    In plain wordsIn people with sepsis, ulinastatin plus thymosin α1 lowered IL-6 levels in pooled trials; the effect of thymosin α1 alone is unknown.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIL-6 level
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    UTI+Tα1 decreased the duration of mechanical ventilation, APACHE II score, and levels of IL-6 and tumor necrosis factor α.
    1 context sentence
    Summary · context
    The meta-analysis included 8 randomized controlled trials (N=1112 patients) on UTI-based therapy for sepsis published before July 10, 2016.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  7. 07HumanNot a test of Thymosin alpha-1 aloneSystematic reviewEfficacy outcome

    In septic patients, ulinastatin combined with thymosin α1 decreased tumor necrosis factor α levels in a meta-analysis.

    In plain wordsIn people with sepsis, ulinastatin plus thymosin α1 lowered tumor necrosis factor α levels in pooled trials; the effect of thymosin α1 alone is unknown.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseTumor necrosis factor α level
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    UTI+Tα1 decreased the duration of mechanical ventilation, APACHE II score, and levels of IL-6 and tumor necrosis factor α.
    1 context sentence
    Summary · context
    The meta-analysis included 8 randomized controlled trials (N=1112 patients) on UTI-based therapy for sepsis published before July 10, 2016.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  8. 08HumanNot a test of Thymosin alpha-1 aloneSystematic reviewEfficacy outcome

    In septic patients, ulinastatin combined with thymosin α1 did not reduce the duration of vasopressor use in a meta-analysis.

    In plain wordsIn people with sepsis, ulinastatin plus thymosin α1 did not shorten vasopressor use in pooled trials; the effect of thymosin α1 alone is unknown.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeDuration of vasopressor use
    Study

    n: not reported in source

    Outcome group
    Intensive care and hospital outcomes · Cardiovascular

    Source sentences

    Summary
    Treatment of UTI+Tα1 did not reduce the duration of vasopressor use and length of intensive care unit stay, or increase IL-10 levels.
    1 context sentence
    Summary · context
    The meta-analysis included 8 randomized controlled trials (N=1112 patients) on UTI-based therapy for sepsis published before July 10, 2016.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  9. 09HumanNot a test of Thymosin alpha-1 aloneSystematic reviewEfficacy outcome

    In septic patients, ulinastatin combined with thymosin α1 did not reduce the length of intensive care unit stay in a meta-analysis.

    In plain wordsIn people with sepsis, ulinastatin plus thymosin α1 did not shorten intensive care stay in pooled trials; the effect of thymosin α1 alone is unknown.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeLength of intensive care unit stay
    Study

    n: not reported in source

    Outcome group
    Intensive care and hospital outcomes · Whole body

    Source sentences

    Summary
    Treatment of UTI+Tα1 did not reduce the duration of vasopressor use and length of intensive care unit stay, or increase IL-10 levels.
    1 context sentence
    Summary · context
    The meta-analysis included 8 randomized controlled trials (N=1112 patients) on UTI-based therapy for sepsis published before July 10, 2016.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  10. 10HumanNot a test of Thymosin alpha-1 aloneSystematic reviewEfficacy outcome

    In septic patients, ulinastatin combined with thymosin α1 did not increase IL-10 levels in a meta-analysis.

    In plain wordsIn people with sepsis, ulinastatin plus thymosin α1 did not raise IL-10 levels in pooled trials; the effect of thymosin α1 alone is unknown.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeIL-10 level
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    Treatment of UTI+Tα1 did not reduce the duration of vasopressor use and length of intensive care unit stay, or increase IL-10 levels.
    1 context sentence
    Summary · context
    The meta-analysis included 8 randomized controlled trials (N=1112 patients) on UTI-based therapy for sepsis published before July 10, 2016.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

Enrolling by invitationNot applicableNCT06966687

Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)

Nanjing Medical Universityn = 2001 Apr 2025 to est. 31 Dec 2026

Aortic Dissection · Aortic Dissection Aneurysm

Trial pageClinicalTrials.govUpdated 14 Jan 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.